Tempest Droneworx won the Best Speed Pitch award at SXSW Pitch earlier this year. Photo via LinkedIn.

It’s not easy to be a standout at South by Southwest, especially during SXSW Interactive, which is the subsection of the festival that focuses on new media, technology and entrepreneurship.

But it’s even more difficult to win at SXSW Pitch, the competition for startups and entrepreneurs that showcases innovative new technology to a panel of industry experts, high-profile media professionals, venture capital investor, and angel investors.

Tempest Droneworx, a Houston-based company that provides real-time intelligence collected through drones, robots and sensors, did just that in March, taking home the Best Speed Pitch award. It was also named a finalist and alternate in the full SXSW Pitch competition. The company is known for it flagship product, Harbinger, a software solution that agnostically gathers data at virtually any scale and presents that data in easy-to-understand visualizations using a video game engine.

Tempest CEO and founder Ty Audronis says his company won based on its merits and the impact it’s making and will make on the world. Audronis founded the company after his hometown of Paradise, California, was destroyed by a wildfire in 2018.

“(SXSW) was a huge moment for our team,” says Audronis, whose background is in science visualization, data visualization and visual effects for the movie industry. “This is about what everyone at Tempest Droneworx has created, and our mission to make sure that issues—like the one that befell Paradise, California, my hometown, and the inspiration for our Harbinger software—don’t become the full-blown (disasters)."

Audronis shares that the company is working to release an agriculture beta this summer and is raising a Tactical Funding Increase (TACFI) round through the AFWERX, the Department of the Air Force’s innovation arm.

Tempest’s Harbinger is impressing investors and clients alike, but what is it exactly and what does it do?

The best way to explain the solution is in how it’s redefining the agriculture space. Tempest has deployed the product at Grand Farm in North Dakota, an agtech operation that seeks to promote sustainable, climate-resilient farming using applied technology.

“We decided to go down the road of agriculture,” Audronis says. “We're currently installed at the Grand Farm in North Dakota, which is a farm that is very closely tied to Microsoft. They do third-party verification of new soils and fertilizers, and we are helping them with visualizing the data that they're getting from their sensors.”

Additionally, Audronis and his co-founder and wife, Dana Abramovitz, spearhead a pilot program at Doubting Thomas Farms, an organic farm in Minnesota, where the company has installed 22 in-ground sensors that can measure volatile organic emissions.

To further optimize their solutions approach, Tempest Droneworx will also train artificial intelligence to look for overspray from neighboring non-organic farms. This will help maintain organic certification and reduce insurance claims for lost crops.

“This will save Doubting Thomas Farms and other organic farms a boatload of cash,” Audronis says.

During an exclusive tour with InnovationMap, Audronis pulled up a live feed of sensors buried around the Minnesota farm up on the conference room display. The feed did, in fact, look like a video game, with the sensors giving real-time data about the farm’s temperature, moisture level, humidity, CO2 and nitrogen.

Harbinger will collect, extract and extrapolate all of the data and later provide a digital almanac for farmers to track the history of their crops.

As the office tour continued, Audronis pointed out the company’s expanding partnership with the U.S. Military.

As a retired U.S. Navy veteran with over two decades of experience designing, building and piloting drones, Audronis understands that Harbinger has multiple military applications that will ultimately save lives—a core tenet of his company’s mission.

The company has launched a robotic dog known as UBU, developed by Tempest partner Ghost Robotics, that enables faster, more accurate ground surveys for explosive devices. This task previously required multiple airmen and hours to complete, Audronis says.

With agriculture and military initiatives in progress and making an impact, Audronis hopes to one day bring his original vision for Tempest Droneworx and Harbinger full circle by getting the call to combat California’s next catastrophic wildfire.

“We're proving our technology in military and in agriculture right now,” Audronis says. “Eventually, I would like to still save some lives with wildfire. That's really the purpose of the company … Whether it's agriculture, smart cities, the bottom line is saving lives through real-time situational awareness."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”